Conditions: Non-Small Cell Lung Cancer
Keywords: Lung Neoplasms Crizotinib
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 27
Healthy volunteers: no

Brief summary:
This is a Phase 1/2 study comparing the safety and anti-tumor activity of erlotinib alone versus erlotinib in combination with PF-02341066 in patients with advanced non-small cell lung cancer.

Detailed description:

Arms:
arm 1: None arm 2: None

Interventions: intervention 1: Erlotinib intervention 2: Erlotinib intervention 3: PF-02341066
Intervention descriptions: intervention 1: Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only) intervention 2: For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2 intervention 3: For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2

Protocol document: